Jacobio Pharma: Focus on Novel Targets
An in-depth overview of the proposed listing of Jacobio Pharmaceuticals using a framework that touches on the science, market opportunity,...
497 Views
Akesobio IPO Initiation: The Tough Get Going
Akeso Biopharma Inc (1495016D CH)Â is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...
589 Views
Biosimilar Battlefield: Unpacking Celltrion
Both Celltrion Inc (068270 KS) and Celltrion Healthcare (091990 KS) have reported preliminary 2018 results with some MD&A. As suspected, Q4's...
754 Views
Amarin Q4 2018 Conference Call--Strong Sales & High Confidence
Q4 2018 Revenues Stronger Than Pre-Announcement on January 4th: Amarin released its Q4 2018 results today and held a conference call. Results of...
856 Views
Biosimilar Battlefield: The Remsima/Inflectra Warning
2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...
830 Views